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Background: The chemical treatment of Plasmodium falciparum for human infections is losing efficacy each year
due to the rise of resistance. One possible strategy to find novel anti-malarial drugs is to access the largest reservoir
of genomic biodiversity source on earth present in metagenomes of environmental microbial communities.
Methods: A bioluminescent P. falciparum parasite was used to quickly detect shifts in viability of microcultures
grown in 96-well plates. A synthetic gene encoding the Dermaseptin 4 peptide was designed and cloned under
tight transcriptional control in a large metagenomic insert context (30 kb) to serve as proof-of-principle for the
screening platform.
Results: Decrease in parasite viability consistently correlated with bioluminescence emitted from parasite microcultures,
after their exposure to bacterial extracts containing a plasmid or fosmid engineered to encode the Dermaseptin
4 anti-malarial peptide.
Conclusions: Here, a new technical platform to access the anti-malarial potential in microbial environmental
metagenomes has been developed.
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Malaria is one of the most important and widely spread
infectious diseases, especially in developing countries,
constituting a major health threat to about 40 % of the
world population [1]. The World Health Organization
(WHO) estimated 207 million new cases of malaria
worldwide in 2012, with over 600,000 deaths as a result
of the severe complications associated with the disease.
At present there is no fully effective vaccine against
malaria, leaving chemotherapy as one of the most
immediate options for fighting this disease [2]. Unfortu-
nately, the number of available anti-malarial drugs with* Correspondence: hernandoa.delportillo@cresib.cat; info@howardjunca.com
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low, and the number of compounds entering clinical trials is
even lower [3], limiting the expected availability of new, ap-
proved compounds for human infections in the near future.
In addition, the rate at which drug resistance is emer-
ging and expanding exceeds the current development of
new drugs, in particular given the lengthy process from
compound characterization to approval for use in humans
[4]. This fact is of particular concern when taking into
account the reports of artemisinin-resistant Plasmodium
falciparum strains in Southeast Asia [5, 6]. Therefore, it is
essential to keep searching for new anti-malarial chemo-
types with novel mechanisms of action.
Efforts in recent years to find anti-malarial compounds
have focused on the exploration of chemical libraries of
public domain, using high-throughput screenings (HTS)
on parasite culture [7–9]. Natural products, which have
been the basis of the majority of current anti-malarialarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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pounds of medical importance as they may include dif-
ferent structures for optimizing therapeutic measures
against malaria. For this reason, research for the identifi-
cation and characterization of new anti-malarial agents
over the past years has gone beyond the study of plants
to include marine organisms, fungi and bacteria [11].
Nowadays it is widely accepted that the microbial
world, besides being the largest fraction of biodiversity
on the planet, is one of the greatest sources for drug
discovery, with frequent applications in human health
[12]. It is very likely that the wide diversity of unexplored
microbial functions may harbour several uncharacterized
molecules, such as metabolites or peptides with potential
therapeutic activity. Efforts to elucidate the genomes from
non-cultured microorganisms (about 99 % of the total
diversity), coupled with the need to discover compounds
with biotechnological potential, has promoted the develop-
ment of metagenomics [13]. This approach involves the
direct extraction of total DNA from a given environment,
which is subsequently cloned and transferred into bacterial
hosts (so far, mainly in Escherichia coli) allowing the
construction of metagenomic libraries. These libraries
are often subjected to functional analysis for phenotypic
identification of a particular activity.
The identification of anti-malarial compounds in
metagenomic libraries is a promising alternative, but
it represents additional technical challenges. Despite
the success in identifying novel drugs from natural
sources, pharmaceutical companies still prefer to carry
out massive screens of pure synthetic compounds [14],
an approach that is difficult in metagenomic libraries.
For instance, the screening of gene libraries requires
assessing parasitic cultures in the presence of complex
bacterial clone extracts on which is hard to identify
potential antiparasitic activity. To overcome this limi-
tation, this research focused on the design and devel-
opment of a non-radioactive methodology to screen
metagenomic libraries for anti-malarial activity using
bacterial extracts. To do this, different extracts ex-
pressing the anti-malarial peptide Dermaseptin S4
(DS4) [15] were tested in order to optimize the experi-
mental conditions that promote antiparasitic activity
detection against a novel P. falciparum bioluminescent
strain. With this purpose, a platform for the parasite
growth consisting of 96-well microplates was estab-
lished, which allowed for both the incubation of multiple
bacterial extracts and the efficient detection of the para-
site’s viability, achieved in a multiple, reproducible and
composite manner. The results gathered here pave the
way for future mid- to large-scale analysis of metage-
nomic library clones, in a novel strategy for the ex-
panded exploration of microbial diversity for anti-
malarial traits by culture independent means.Methods
Parasite cultures
The transgenic P. falciparum 3D7/pHDEF1-luc line [16]
was grown continuously following the method of Trager
and Jensen [17], under the selective pressure of drug
WR99210 (Sigma-Aldrich, Saint Louis, USA). Parasites
were cultured in complete medium consisting of RPMI
1640 with L-glutamine (Sigma), 25 mM HEPES (Sigma),
25 mM sodium bicarbonate (Sigma), 0.1 mM hypoxan-
thine (Sigma), 0.5 % Albumax II (Invitrogen, Carlsbad,
USA), 50 μg/L gentamicin (Life Technologies, Carlsbad,
USA) and human blood type O at 1.5–3 % haematocrit.
The stock cultures were maintained in a 1–3 % parasit-
aemia range, under an atmosphere containing 5 % CO2,
5 % O2 and 90 % N2 at 37 °C.
Isotopic and luminescence assays
The isotopic detection protocol used has been described
by Desjardins et al. [18], except for the addition of
the radioactive marker [3H]-labelled hypoxanthine. The
assay was carried out in 96-well plates containing 130–
200 μL of parasite culture at 1 % parasitaemia and 1 %
haematocrit per well. For luciferase detection, parasite
survival was evaluated after 48–72 h of drug or bacterial
extract exposure and incubation at 37 °C. Briefly, the test
plate was centrifuged and the supernatant discarded,
while the remaining pellets were re-suspended in 10 μL
of cell culture lysis buffer (10 mM Tris pH 7.5, 1 mM
EDTA, 2 % Triton X-100 and 0.15 % saponin) and trans-
ferred to a 96-well, white, flat-bottom plate (Thermo
Scientific, Waltham, USA). Then 10 μL of luciferase
assay substrate (Promega, Fitchburg, USA) were added
to each well, mixed for 60 s in a shaker and the lucifer-
ase activity (total light) measured in the TECAN GENios
(Tecan, Männedorf, Switzerland) in terms of relative
luminescence units (RLUs).
Parasite growth inhibition tests
To perform inhibition tests, the parasite cultures were
first synchronized with 5 % sorbitol (Sigma), as de-
scribed elsewhere [19]. Parasite growth inhibition by
drugs was tested using serial dilutions of chloroquine,
mefloquine, artesunate, and amantadine. The 50 % in-
hibitory concentration (IC50) values were calculated
from three different experiments in duplicates using the
software LN-NonLin (V 1.05 Beta), based on a polyno-
mial regression model. Parasite growth inhibition tests
using bacterial extracts (see below) were done in tripli-
cates using 8, 16 or 32 μL of each extract in 130 μL final
volume per well, following the described procedures for
parasite culture. Finally, the parasite growth ratio was
determined according to the following formula: [(RLUs
experimental sample - RLUs negative control)/(RLUs
positive control - RLUs negative control)] × 100.
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To select the peptide with anti-malarial activity to be
used in this study, the literature was reviewed to find
those that showed good antiparasitic activity in concen-
trations that were at least one order of magnitude lower
than those required to have toxic effects on human cells.
The peptide selection criteria included linear structure, a
capacity to inhibit growth of P. falciparum by at least
50 % at concentrations below 20 μM, and activity detect-
able within a 72-h period. The peptide DS4 [15, 20] was
chosen, being characterized by having a sequence of 38
amino acids and an IC50 range of 0.27–2.2 μM against P.
falciparum strains sensitive and resistant to chloroquine.
Dermaseptin 4 coding gene design
The DS4 coding sequence (CDS) was determined based
on the more robust codons for E. coli K12 strain, using
the peptide’s sequence (ALWMTLLKKVLKAAAKAALN
AVLVGANA) [15] as a query in Optimizer [21]. The
first codon (ATG) was included in the CDS. The arabinose
promoter (PBAD) and the ribosomal RNA B transcriptional
termination region, both from pBAD18 plasmid, were in-
cluded in silico upstream and downstream on DS4 CDS,
respectively [22]. Secondary structure prediction of the
theoretical mRNA sequence was performed by Mfold [23],
choosing only the −4 to +37 pair bases around the ATG.
The complete designed gene was chemically synthesized
(Genscript, Piscataway, USA) and subsequently cloned in
the unique EcoRV restriction site of pUC57 plasmid
(pUC57_DS4).
Synthetic gene cloning and RT-PCR
With pUC57_DS4 as template full ds4 gene amplification
was performed using the following primers: 5′-ggcgcgccA
CTTTTCATACTCCCGC-3′ and 5′-ggcgcgccTGTATC
AATAAAACGAAAGG-3′ (AscI restriction sites shown
in lower case). The amplified product was cloned into
the unique AscI restriction site of pCC2FOS_F076
(F076), a fosmid containing a metagenomic insert ob-
tained from soil DNA libraries of potato agricultural
plots in Colombian Andes (Proyecto CIMA, Ministerio
de Agricultura, República de Colombia). The fosmid
DNA sequence was obtained by 454 technology (Selah
Genomics, Greenville, USA) (fosmid sequence data as-
sembled and kindly provided by JC García-Betancur,
Molecular Biotechnology - CorpoGen & IMIB - U.
Würzburg). The final DNA construct (clone F076_DS4)
was confirmed by sequencing.
To assess ds4 transcription from the synthetic gene, RNA
was extracted from E. coli Epi300 bacterial clones (Illumina
Inc, San Diego, USA) harbouring one of the following
vectors: pUC57 (empty plasmid vector), pUC57_DS4,
pCC2FOS (empty fosmid vector), pCC2FOS_F076 or
pCC2FOS_F076_DS4. Briefly, each bacterial clone wasgrown to 0.4–0.8 OD600nm in LB medium with chloram-
phenicol (20 μg/mL) or ampicillin (100 μg/mL), depending
on the vector backbone of each episomal DNA. Peptide
expression was repressed or induced, respectively, with
0.1 % D-glucose or 0.2 % L-arabinose for four additional
hours at 37 °C. RNA extraction was performed on every
cell pellet using the Direct-zol RNA MiniPrep kit (Zymo
Research, Irvine, USA). RNA samples were treated with
RQ1 RNase-Free DNase (Promega), quantities normalized,
and then subjected to reverse transcription using 15 ng/
μL of random hexamers and SuperScript III Reverse Tran-
scriptase (Invitrogen), following the manufacturer’s rec-
ommendations. Subsequently, the coding length for the
DS4 peptide was amplified by PCR using the primers
DS4-F (5′-ATGGCCCTGTGGATGACCCT-3′) and DS4-
R (5′-TCAGGCGTTGGCACCG-3′).
Peptide expression and whole protein extraction
To obtain whole bacterial extracts post induction with
L-arabinose, transformed E. coli Epi300 cells were grown
as explained above. Bacterial cultures were normalized
by optical density (OD) and their respective pellets were
washed three times with PBS, re-suspended in 1/20 of the
original volume in PBS and lysed by sonication for 2 min
in a Qsonica Q500 sonicator (Cole-Parmer, Vernon Hills,
USA), using 1 s pulse, 1 s rest and 12 % amplitude. Result-
ing lysed cultures were filtered (0.22 μm), quantified using
the Bradford assay [24], and normalized based on the
extract that showed the lowest soluble protein concen-
tration. All the bacterial extracts were assessed on P.
falciparum 3D7/pHDEF1-luc culture as described.
Results
The development of a stable P. falciparum 3D7 trans-
genic line, capable of expressing the firefly luciferase
gene under the control of the intergenic region of Plas-
modium berghei elongation factor 1 (EF-1α) gene has
been previously reported [16]. Moreover, a remarkable
sensitivity of the luciferase assay using this transgenic
parasite and a well-correlated linear relationship be-
tween luminescence and parasite density (r = 0.98) has
been observed. Plasmodium falciparum 3D7/pHDEF1-luc
was therefore used to develop a method for biolumines-
cence detection in 96-well microplates by assessing if
parasite bioluminescence, as a determinant of parasite
growth, was comparable to standard radioactive detection
methods [18, 25]. Four anti-malarial drugs with different
mechanisms of action were tested in vitro against P. falcip-
arum 3D7/pHDEF1-luc cultures. Results demonstrated
that IC50 values using the luciferase assay were not signifi-
cantly different from the ones using the hypoxantine
method (Table 1). The high variability observed in the
triplicates of mefloquine is not uncommon in these assays
[26]. Therefore, this transgenic parasite can be used to
Table 1 IC50 comparison (mean ± SD) for the anti-malarial
compounds tested by two detection methods
Detection
method
Anti-malarial drug
Chloroquine
(nM)
Mefloquine
(nM)
Artesunate
(nM)
Amantadine
(μM)
Isotopic 10.18 ± 2.37 17.28 ± 8.38 1.05 ± 0.57 112.31 ± 24.03
Luciferase 10.36 ± 0.75 15.83 ± 7.40 0.81 ± 0.47 132.24 ± 43.08
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potential anti-malarial compounds, as already shown
for other bioluminescent transgenic lines similarly con-
structed [9, 27].
The DS4 peptide was chosen for the design of a gene
capable of promoting anti-malarial activity when expressed
in E. coli. This linear peptide, isolated from the skin glands
of Phyllomedusa sauvagii frogs, has shown anti-
malarial effect (evidenced by radiolabeled hypoxanthine
parasite incorporation) on both chloroquine-sensitive
and resistant P. falciparum strains, with IC50 values
ranging from 0.27 to 2.2 μM [15]. The coding sequence
for DS4 peptide was designed based on the most robust
E. coli codons, different from the common approach of
using the most frequent codons or those which optimize
the codon adaptation index (CAI) [28]. This has been
shown to be a determinant for efficient expression of some
recombinant proteins, primarily determined by the avail-
ability of the amino-acylated (charged) tRNAs and not by
the total levels of tRNAs [29]. Transcription of this coding
sequence is controlled by an upstream ribosome-binding
site (RBS) and the arabinose promoter (PBAD), and a
downstream transcriptional terminator region (Fig. 1).
The in silico identification of secondary structures in
the region −4 to +37 (from the first ATG codon)
showed a single secondary structure with a free energy
value of −7.5 kcal/mol, much higher than the values
reported as detrimental for an efficient initiation of re-
combinant protein synthesis in E. coli [30].
Once the ds4 synthetic gene was obtained, it was ampli-
fied and inserted into a unique restriction site of the
metagenomic insert of pCC2FOS_F076. After trans-
forming both episomal DNAs harbouring the ds4 geneFig. 1 DS4 coding gene and F076_DS4 construct development. Scaled diagra
from the arabinose inducible promoter (PBAD). The final construction in fosmid
shown. araO2, araO1 and araI1-I2: promoter regulator regions; CAP: catabolite
B transcriptional termination region; MI: metagenomic insert; pCC2FOS: fosmi
predicted in the MI with a minimum length of 450 pb, that started only with(pUC57_DS4 and F076_DS4) in E. coli Epi300, gene
transcription was validated by independent induction
of bacterial gene expression with L-arabinose, com-
pared with the same DNAs lacking the ds4 gene
(Fig. 2a). The PBAD was able to both promote ds4 gene
transcription from the F076_DS4 construct (in the con-
text of metagenomic DNA), and to tightly repress the
ds4 transcription by incubating the bacterial culture
with D-glucose (Fig. 2b). Since there are no previous
reports of recombinant DS4 peptide expression it is im-
portant to mention that the regulatory system used in
this research, based on the interaction of PBAD with the
AraC protein, has proven to be quite useful for the ex-
pression of potentially toxic proteins [22]. Although the
AraC protein is essential for transcription from PBAD
[31], its encoding gene was not included in the syn-
thetic ds4 gene. This is due to the fact that the E. coli
Epi300 strain used has a genomic copy of the araC
gene that supplies that regulatory function [32]. There-
fore, DS4 peptide expression from the designed syn-
thetic gene proposed in this research is restricted to
bacterial hosts that express the AraC protein.
Parasitic growth inhibition assays were performed
using the cell pellet extracts (concentrated samples)
from E. coli Epi300 pUC57_DS4 and the metagenomic
clone E. coli Epi300 F076_DS4, compared with the con-
trols not expressing the DS4 peptide. The DS4 peptide is
lipophilic and has high electrostatic affinity for cell
membranes [33], a partition that would result in a rela-
tive decrease of its concentration in the soluble fraction,
after using the non-denaturing extraction protocol pro-
posed. After standardizations, significant anti-malarial
activity was observed using bacteria expressing the DS4
peptide from plasmid and fosmid DNAs (Fig. 3), demon-
strating the feasibility of this approach. It is important to
note that the bacterial pellet extracts from E. coli harbour-
ing either one of the episomal DNAs lacking the antimal-
arial DS4 peptide coding gene (pUC57, pCC2FOS or
pCC2FOS_F076) had per se an inhibitory growth effect on
the parasite proportional to the amount of bacterial ex-
tract used. Thus, it is necessary to normalize bacterial ex-
tract concentration when testing multiple metagenomicm of the gene designed to control DS4 anti-malarial peptide expression
F076_DS4 harboring the ds4 gene in the metagenomic insert is also
activator protein binding site; RBS: ribosome binding site; rrnB term: RNA
d vector. Horizontal black arrows represent all open reading frames (ORFs)
ATG
Fig. 2 DS4 coding gene transcription from different episomal DNAs. a DS4 CDS amplification from cDNAs of bacterial cultures grown in the
presence or absence of L-arabinose: 1 - E. coli Epi300 pCC2FOS_F076; 2 - E. coli Epi300 pUC57; 3 - E. coli Epi300 F076_DS4; 4 - E. coli Epi300
pUC57_DS4. +, indicate the cultures that were induced with L-arabinose, while the rest of the samples did not include the inducer. b DS4 CDS
amplification from cDNAs from E. coli Epi300 F076_DS4, after being incubated with the repressor (D-glucose) or the inductor (L-arabinose) of gene
transcription. -, PCR mix without DNA; +, positive control for the PCR (with pUC57_DS4 as a template); 1, cDNA from bacterial culture incubated
with D-glucose; 2, cDNA from bacterial culture incubated with L-arabinose; *, RT-PCR reactions without reverse transcriptase; MWM, molecular
weight marker
Fig. 3 Anti-malarial activity with extracts from bacterial pellets. Parasite
growth inhibition upon incubation of the transgenic P. falciparum
3D7/pHDEF1-luc with different volumes of L-arabinose-induced
E. coli Epi300 extracts. a Parasite growth inhibition with extracts
derived from E. coli Epi300 transformed with pUC57 or pUC57_DS4.
b Parasite growth inhibition with extracts derived from E. coli Epi300
transformed with pCC2FOS, pCC2FOS_F076 (F076) or F076_DS4. Error
bars represent SD; *, p <0.05 by paired Student’s t-test
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the inhibitory effect of the extract itself, avoiding false
positives. These results showed that bacterial extracts
expressing the recombinant anti-malarial DS4 peptide
exerted overall significantly higher parasite mortalities
when compared to the effect of the extracts alone. This
system can be used to screen bacterial extracts with
metagenomic-encoded information for anti-malarial ac-
tivities using the tested and optimized bioluminescent
assay for P. falciparum viability in a 96-well format.
Conclusions
Here, the development of a novel screening platform for
exploring novel anti-malarial activities encoded in the
information held in metagenomic libraries is reported.
The platform involved the establishment of malarial
parasite cultures in 96-well plates using a novel P. falcip-
arum bioluminescent strain and the construction of a
bacterial clone capable of expressing a peptide with
anti-malarial activity in the context of whole bacterial
extracts. This bacterial clone serves as a positive con-
trol for anti-malarial activity in current and future ana-
lyses of clones from genomic/metagenomic libraries of
diverse and scarcely explored sources. The combined
use of these components defined a tool aiming to facili-
tate the retrieval of novel anti-malarial compounds
from metagenomic libraries containing information
originated from diverse microbial communities as po-
tential novel sources for chemotherapy developments.
However, future assays should be focused on increasing
the metagenomic clone screening rates. One approach
could include the assessment of antimalarial activities
by bacterial extract pools or in 384-well plate format.
Alternatively, metagenomic libraries with improved
functional expression profiles (e.g. from multiple bacterial
hosts and libraries constructed in vectors including
strong-flanking promoters) or containing high proportion
of microorganisms more related to the screening host may
Mongui et al. Malaria Journal  (2015) 14:233 Page 6 of 6be appropriate starting points for antimalarial-research
studies from metagenomic libraries.
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